New Pill Doubles Survival in Pancreatic Cancer Patients in Landmark Trial
Daraxonrasib nearly doubled survival vs. standard chemo in a major ASCO trial — a potential turning point for one of cancer's deadliest diagnoses.
Summary
A targeted oral drug called daraxonrasib has shown unprecedented results in pancreatic cancer, nearly doubling survival time compared to standard chemotherapy in a clinical trial. The study, presented at the American Society of Clinical Oncology's annual meeting and published simultaneously in the New England Journal of Medicine, marks a historic milestone for a disease with notoriously poor outcomes. Developed by Revolution Medicines, daraxonrasib is a pill that targets specific cancer-driving mutations. Pancreatic cancer has long resisted most treatment advances, making this result particularly significant. Oncologists described the findings as practice-changing, with one specialist of 16 years moved to tears upon hearing the results. While full details are paywalled, the top-line survival data represents a meaningful leap forward in treatment options.
Detailed Summary
Pancreatic cancer is one of the most lethal malignancies known, with five-year survival rates typically below 12% and few meaningful treatment advances in decades. That context makes the new findings around daraxonrasib, a targeted oral therapy developed by Revolution Medicines, genuinely extraordinary. Presented at the flagship plenary session of the 2026 American Society of Clinical Oncology meeting and simultaneously published in the New England Journal of Medicine, the results have already drawn widespread attention from the oncology community.
The headline finding is striking: patients treated with daraxonrasib lived nearly twice as long as those receiving standard chemotherapy. In a field where incremental gains of weeks are celebrated, a near-doubling of survival represents a qualitative shift in outcomes. Physicians who have spent careers treating this disease described the results as unlike anything they had previously witnessed.
Daraxonrasib appears to work as a targeted therapy, likely aimed at RAS pathway mutations that drive many pancreatic cancers. RAS mutations have historically been considered undruggable, so a pill-form inhibitor showing this magnitude of clinical benefit would represent a major scientific breakthrough as well as a clinical one.
For health-conscious adults and those with family histories of pancreatic cancer, this development signals that the therapeutic landscape may be shifting meaningfully. While not yet approved, the data strength and the prestige of the publication venue suggest regulatory review could move quickly if results hold under scrutiny.
Important caveats remain. The full trial data is behind a paywall, limiting independent assessment of methodology, patient selection, mutation-status criteria, and side effect profiles. It is also unclear how broadly applicable the results are across pancreatic cancer subtypes. Independent replication and regulatory review will be essential next steps before this becomes standard of care.
Key Findings
- Daraxonrasib nearly doubled overall survival vs. standard chemotherapy in a pancreatic cancer clinical trial.
- Results were published in the New England Journal of Medicine and presented at ASCO 2026 plenary.
- The drug is an oral pill, offering a more convenient delivery method than infused chemotherapy.
- Oncologists called the findings practice-changing — an unprecedented outcome in pancreatic cancer treatment.
- The therapy likely targets RAS pathway mutations, historically considered undruggable in solid tumors.
Methodology
This is a news report from STAT News summarizing a phase trial presented at ASCO 2026 and published in the New England Journal of Medicine, both high-credibility sources. The article is partially paywalled, limiting access to full trial methodology, sample size, and safety data. Evidence basis is a manufacturer-sponsored clinical trial, which warrants attention to potential bias.
Study Limitations
Full trial data is behind a paywall, preventing detailed review of patient demographics, mutation-selection criteria, adverse events, and follow-up duration. The trial was conducted by the drug's manufacturer, introducing potential sponsorship bias that independent review will need to address. Regulatory approval, broader applicability across cancer subtypes, and long-term outcomes remain to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.